drugset / Trial / NCT02472366

A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

NCT02472366

Phase 4 Completed 16 enrolled Alimera Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients insufficiently responsive to available therapies.

Timeline

Start
2014-01
Primary completion
2015-03
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject fluocinolone acetonide Small molecule